Key result
CYP2C19*2 status associated with ~33% higher platelet reactivity versus wild-type in CAD patients on clopidogrel.
Why the study?
The influence of CYP 2C19*2 polymorphism on platelet inhibition during clopidogrel treatment in symptomatic coronary artery disease patients was unclear.
Does the CYP 2C19*2 polymorphism increase platelet reactivity and clopidogrel resistance in patients with stable CAD on single antiplatelet treatment with clopidogrel?
Population
219 clopidogrel-treated patients with symptomatic coronary artery disease
Comparison
Patients with CYP 2C19*2 polymorphism (GA/AA) vs wild-type (GG) patients
Design
Randomized open-label study with platelet function testing
Authors
Loading...
CYP2C19*2 may identify reduced clopidogrel response in CAD; leaves open whether genotyping improves outcomes.
Observational (n=219)
Open-label
No
Does the CYP 2C19*2 polymorphism increase platelet reactivity and clopidogrel resistance in patients with stable CAD on single antiplatelet treatment with clopidogrel?
Absolute Event Rate: 50.9% vs 38.3%
p-value: p=0.001
Patients with stable CAD on single clopidogrel therapy carrying the CYP 2C19*2 polymorphism exhibit significantly higher platelet reactivity and clopidogrel resistance compared to wild-type patients.
Pettersen et al. (2011) conducted an observational in Stable symptomatic coronary artery disease (n=219). CYP 2C19*2 polymorphism (GA/AA) vs. Wild-type (GG) was evaluated on Platelet reactivity measured by VASP-PRI (p=0.001). Patients with stable coronary artery disease on single clopidogrel treatment carrying the CYP2C19*2 polymorphism had significantly higher platelet reactivity compared to wild-type patients (VASP-PRI 50.9% vs 38.3%, p=0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: